About us

Bavarian Nordic UK is protecting our tomorrow with an aim to become the UK’s preferred and trusted partner for travel vaccines.

Protecting our tomorrow

Combining a rich heritage in vaccine development and a supply chain spanning R&D, manufacturing and commercialisation, Bavarian Nordic UK  is protecting our tomorrow with an aim to become the UK’s preferred and trusted partner for travel vaccines. 

Amidst rising travel from the UK to destinations with risk of preventable travel-related infection,1 Bavarian Nordic UK has launched with a dedicated travel vaccines portfolio in rabies, cholera, typhoid and chikungunya.2–6 And we were at the forefront of the UK government’s response to mpox, providing the first approved non-replicating vaccine.7–9

We’re standing side by side with vaccination providers, ready to support the uptake and success of travel health services.

A HCP giving a young girl an injection

Building on a legacy of vaccine achievements

With pride in our achievements in vaccine development over the past 30+ years, we are focused on the future.

Right now, we are working on bringing communities around the globe an even greater degree of protection from infectious disease.

IMVANEX®▼ Smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara) is currently supplied directly to the UK government for use in the mpox programme.

Imvanex is indicated for the active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in individuals 12 years of age and older.

The use of this vaccine should be in accordance with official recommendations.

Vimkunya®▼ Chikungunya vaccine (recombinant, adsorbed) is the latest6 addition to our travel portfolio and helps to protect travellers aged 12 years and older against chikungunya.6

VIMKUNYA® is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older.

The use of this vaccine should be in accordance with official recommendations.

 

1

1994

Bavarian Nordic A/S founded in Denmark

2

2019

Acquisition of Rabipur® (Rabies Vaccine) from GlaxoSmithKline plc10

3

2022

EU approval of mpox vaccine, IMVANEX®▼ Smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara) in adults 11

4

2023

Acquisition of Vivotif® (Typhoid Vaccine, Live, Oral), Vaxchora® (Cholera Vaccine, Live, Oral) and pipeline assets from Emergent BioSolutions12

5

2025

Bavarian Nordic UK launched to market Rabipur®, Vivotif®, Vaxchora® and Vimkunya®▼ chikungunya vaccine (recombinant, adsorbed) in the UK3–6

Protecting tomorrows today 

We’re focused on and pledge our commitment to four areas:

 

Ensuring reliable supply of vaccines

Being a trusted partner

Continued R&D investment

Applying our innovative spirit to provide leadership in infectious diseases and travel health

Prescribing Information for our vaccines

IMVANEX®

Click for IMVANEX® Prescribing information (External Link)

RABIPUR®

Click for RABIPUR® Prescribing information (External Link)

VIMKUNYA®

Click for Vimkunya® Prescribing information (External Link)

VIVOTIF®

Click for VIVOTIF® Prescribing information (External Link)

VAXCHORA®

Click for VAXCHORA® Prescribing information (External Link)

Order your vaccines

Our vaccines are distributed in the UK by Polar Speed. To place an order, you’ll need a Bavarian Nordic/Polar Speed account.

Order your vaccines

Published date: 1 May 2026

UK-CHIK-2600008 | May 2026

  1. Office for National Statistics. Travel trends 2023. Travel trends estimates: UK residents visits abroad. October 2024. Accessed May 2026. https://www.ons.gov.uk/peoplepopulationandcommunity/leisureandtourism/datasets/ukresidentsvisitsabroad (External Link)
  2. GOV.UK. Travel-associated infections in England, Wales and Northern Ireland: 2022. Updated 14 August 2025. Accessed May 2026. https://www.gov.uk/government/publications/travel-associated-infections/travel-associated-infections-in-england-wales-and-northern-ireland-2022 (External Link)
  3. Rabipur Summary of Product Characteristics.
  4. Vaxchora Summary of Product Characteristics.
  5. Vivotif Summary of Product Characteristics.
  6. Vimkunya (Chikungunya vaccine, recombinant, adsorbed), Summary of Product Characteristics
  7. GOV.UK. The UK secures more vaccines to help boost resilience against mpox. Published 16 September 2024. Accessed May 2026. https://www.gov.uk/government/news/uk-secures-more-vaccines-to-help-boost-resilience-against-mpox (External Link)
  8. IMVANEX Summary of Product Characteristics.
  9. GlobeNewsWire. Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Switzerland. Published 13 March 2024. Accessed May 2026. https://www.globenewswire.com/news-release/2024/3/13/2845416/0/en/Bavarian-Nordic-Receives-Approval-of-Smallpox-and-Mpox-Vaccine-in-Switzerland.html.html. (External Link)
  10. Bavarian Nordic. Bavarian Nordic announces a transformative acquisition of two established vaccines from GlaxoSmithKline. Published 21 October 2019. Accessed May 2026. https://www.bavarian-nordic.com/investor/news/news.aspx?news=5774 (External Link)
  11. European Medicines Agency. Mpox. Accessed May 2026. https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/mpox (External Link)
  12. Bavarian Nordic. Bavarian Nordic completes acquisition of travel vaccine portfolio from Emergent BioSolutions. Published 15 May 2023. Accessed May 2026. https://www.bavarian-nordic.com/investor/news/news.aspx?news=6768 (External Link)